Anti-Human CD64 (FCGR1) [Clone 10.1] — Purifiedin vivoPLATINUM™ Functional Grade,Leinco,I-2015

Host

Mouse

Reactivity

Human

Application

FA,FC,in vivo

Platform ID

BAB259904134

Leinco

Headquarters

410 Axminister Drive St. Louis, Missouri 63026

Contact

Tel: +1 (800) 538-1145,+1 (636) 230-9477
Fax:

Product Specifications
Scientific Background

Specifications

NameAnti-Human CD64 (FCGR1) [Clone 10.1] — Purifiedin vivoPLATINUM™ Functional Grade
Cat. No.I-2015
HostMouse
ReactivityHuman
ApplicationFA,FC,in vivo
Clone Number10.1
Concentration≥ 5.0 mg/ml
ImmunogenRheumatoid synovial fluid cells and fibronectin purified human monocytes.
Purity≥98% monomer by analytical SEC ⋅ >95% by SDS Page
Endotoxin Level≤ 0.5 EU/mg as determined by the LAL method
ShippingNext Day 2-8°C
FormulationThis monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
StorageFunctional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Scientific Background

FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNγ and G-CSF 1 . FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG4 2 , resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation 1,3 . CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis 4 . In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages 5 .

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.